NRX Pharmaceuticals, Inc. (NRXP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.66
- As of
Kresmion compiles this page from NRXP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
NRX Pharmaceuticals, Inc. (NRXP): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-16.
See the full NRXP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NRXP on one page. Preview it with sample data, then open it live with a free account.
Preview the NRXP dossierActive events for NRXP
- high13F: funds added
5 tracked funds increased NRXP this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 773.8%, EPS $-0.44 vs $0.0653 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +1800% to NRXP (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +526% to NRXP (2026Q2)
- medium13F: new position
MILLENNIUM MANAGEMENT LLC new position in NRXP
FREE, NO ACCOUNT
Every event on NRXP, as it fires
You are seeing 5 of 11 events recorded on NRXP since 2026-06-10.
The five above landed across 3 days. The other 6 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
NRXP positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP 629444209 · 2026Q2 | $2.8M | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 629444209 · 2026Q2 | $158K | 0.00% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 629444209 · 2026Q2 | $108K | 0.00% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 629444209 · 2026Q2 | $50K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NRXP
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on NRXP
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in NRXP on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on NRXP in the last 180 days.
Upstream: SEC EDGAR filings for NRXP
Kresmion, "NRX Pharmaceuticals, Inc. (NRXP) institutional holdings and SEC filings", data as of 2026-10-16, https://kresmion.com/research/NRXP. Upstream data: SEC EDGAR filings for NRXP.
Link to this data (HTML):
<a href="https://kresmion.com/research/NRXP">NRX Pharmaceuticals, Inc. (NRXP) institutional holdings and SEC filings (Kresmion)</a>
Follow NRXP on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to NRXP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.